Table 1.
Background characteristics
| N | Overall (N = 171) |
Severe GHD− (N = 116) |
Severe GHD+ (N = 55) | P | |
|---|---|---|---|---|---|
| Age, y | 171 | 54 ± 16 | 52 ± 17 | 56 ± 14 | .13 |
| Male sex, N (%) | 171 | 67 (39) | 37 (32) | 30 (55) | .007 |
| BMI, kg/m2 | 171 | 23.5 ± 3.8 | 23.0 ± 3.7 | 24.6 ± 3.7 | .009 |
| BMI >25 kg/m2 | 53 (31) | 28 (24) | 25 (35) | .008 | |
| Hypertension, N (%) | 171 | 57 (33) | 36 (31) | 21 (38) | .39 |
| Diabetes mellitus, N (%) | 171 | 25 (15) | 15 (13) | 10 (18) | .36 |
| Dyslipidemia, N (%) | 171 | 115 (67) | 71 (61) | 44 (80) | .02 |
| Clinical diagnosis, N (%) | 171 | ||||
| NF-PitNET | 100 (58) | 61 (53) | 39 (71) | .02 | |
| RCC | 71 (42) | 55 (47) | 16 (29) | ||
| Pituitary mass volume, mm3 | 171 | 2198 (777-5526) | 1378 (554-3235) | 6416 (2753-9734) | <.001 |
| Number of anterior pituitary hormone deficits, N (%) | 171 | ||||
| 0 | 95 (56) | 95 (82) | 0 (0) | <.001 | |
| 1 | 36 (21) | 20 (17) | 16 (29) | ||
| 2 | 17 (10) | 1 (1) | 16 (29) | ||
| 3 | 11 (6) | 0 (0) | 11 (20) | ||
| 4 | 12 (7) | 0 (0) | 12 (22) | ||
| Corticotroph deficiency, N (%) | 171 | 26 (15) | 2 (2) | 24 (44) | <.001 |
| Hypothyroidism, N (%) | 171 | 31 (18) | 9 (8) | 22 (40) | <.001 |
| Hypogonadotropic hypogonadism, N (%) | 171 | 39 (23) | 11 (9) | 28 (51) | <.001 |
| hs-CRP, ng/mL | 171 | 348 (148-796) | 249 (113-537) | 754 (393-1330) | <.001 |
| AST, U/L | 171 | 20 (17-26) | 20 (15-25) | 23 (19-31) | .001 |
| ALT, U/L | 171 | 17 (12-25) | 16 (12-23) | 19 (14-28) | .03 |
| GGT, U/L | 170 | 20 (14-33) | 18 (13-31) | 24 (17-42) | .01 |
| Elevated liver enzymes, N (%) | 171 | 42 (25) | 22 (19) | 20 (36) | .02 |
| HbA1c, % | 171 | 5.7 (5.5-6.1) | 5.7 (5.5-6.0) | 5.8 (5.4-6.1) | .30 |
| Creatinine, mg/dL | 171 | 0.70 (0.61-0.83) | 0.68 (0.59-0.78) | 0.79 (0.63-0.86) | .003 |
| Estimated GFR, mL/min/1.73 m2 | 171 | 77.6 ± 15.7 | 79.2 ± 15.7 | 74.1 ± 15.4 | .05 |
| HDL-cholesterol, mg/dL | 171 | 56 (48-70) | 61 (50-73) | 53 (41-59) | .001 |
| LDL-cholesterol, mg/dL | 171 | 121 (100-146) | 112 (93-134) | 136 (115-162) | <.001 |
| Triglyceride, mg/dL | 171 | 96 (71-132) | 86 (64-119) | 121 (90-181) | <.001 |
| Peak GH response to GHRP-2, ng/mL | 171 | 16.1 (5.0-34.8) | 27.0 (15.6-43.6) | 2.5 (1.3-4.7) | <.001 |
| IGF-1, ng/mL | 171 | 104 (77-141) | 122 (91-149) | 75 (51-106) | <.001 |
| IGF-1 SD score | 171 | −1.1 ± 1.4 | −0.7 ± 1.2 | −2.0 ± 1.5 | <.001 |
| Free thyroxine, ng/mL | 171 | 1.14 ± 0.26 | 1.23 ± 0.21 | 0.96 ± 0.26 | <.001 |
| Total testosterone (male), ng/mL | 67 | 357 ± 213 | 475 ± 146 | 212 ± 193 | <.001 |
Data are presented as mean ± SD or median (interquartile range).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ-glutamyl transpeptidase; GFR, glomerular filtration rate; GHD, GH deficiency; GHRP-2, GH-releasing peptide-2; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; NF-PitNET, nonfunctioning pituitary neuroendocrine tumor; RCC, Rathke cleft cyst.